产品分类

您的位置:首页 > 公司新闻 > Life Technologies 接受赛默飞136亿美金现金收购报价

公司新闻

Life Technologies 接受赛默飞136亿美金现金收购报价

时间:2013-04-18 浏览次数:1988

关键词: 赛默飞 Life Technologies 收购

 

据路透社4月15日电,Life Technologies公司接受了Thermo Fisher 136亿美元现金的收购报价,这将是迄今为止生命科学领域内zui大的企业并购。

预计,此项交易将在2014年初完成,并加入其调整后每股盈余。

赛默飞执行官Marc Casper 在一份声明中说,“收购Life Tech增强了我们增长战略的所有三个要素:科技创新、*的客户价值主张和在新兴市场的扩张。”(生物谷Bioon.com)

英文原文:
http://www.reuters.com/article/2013/04/15/us-lifetechnologies-thermofisher-idUSBRE93D0A620130415

(Reuters) - Genetic testing equipment maker Life Technologies Corp has accepted a $13.6 billion cash buyout proposal from scientific and laboratory instruments company Thermo Fisher Scientific Inc in one of the year's biggest corporate takeovers.

The deal, announced on Monday, values Life Tech at $76 per share and would catapult Thermo Fisher into the hot field of genetic sequencing, where researchers, drugmakers and doctors are uncovering the hereditary factors underpinning diseases to better tailor treatments to patients.

The offer represents a premium of about 12 percent to Life Tech's market close on Friday.

Life Tech shares were up 7.7 percent at $73.24 in morning trading, while Thermo Fisher rose 3.4 percent to $82.30.

William Blair analyst Amanda Murphy said the deal price was at the high end of market expectations of $65 to $75 per share.

Thermo Fisher expects the transaction to close early in 2014 and immediay add to earnings before special items. It still requires U.S. regulatory and shareholder approvals.

Thermo Fisher will also assume Life Tech's net debt of about $2.2 billion. In the third year following the deal's closing, the company said it expected to achieve cost savings of $250 million by consolidating facilities and support functions.

Life Technologies explored a sale after previous attempts by Chief Executive Officer Gregory Lucier to boost the value of the company's stock and capture more market share from rival Illumina Inc proved unsuccessful.

Illumina had already demonstrated the appeal of gene-sequencing companies that help analyze a person's genetic blueprint to develop personalized medical treatment. Drugmaker Roche Holding AG had made a $6.8 billion hostile offer for Illumina last year but walked away when the company demanded a higher price.

Thermo Fisher's products range from basic scientific equipment, such as test tubes, to advanced mass spectrometry equipment used to determine the chemical structure of molecules. It also sells chemicals, agents and antibodies used in the manufacturing and research of biotech medicine, and in recent years has increased its portfolio of products for testing air and water quality and food safety.

The Life Technologies deal would boost Thermo Fisher's presence in scientific research, genetic analysis and applied sciences. Thermo Fisher has been quite acquisitive in recent years, buying Phadia for $3.5 billion in 2011 and Dionex for $2.1 billion in 2010.

Thermo Fisher has obtained committed bridge financing from J.P. Morgan and Barclays, which also acted as the company's financial advisers.

Life Tech' board met on Saturday to review three takeover offers.

Sources familiar with the matter told Reuters on Sunday the company chose Thermo Fisher over Sigma-Aldrich Corp, a maker of chemicals for research laboratories, and a private equity consortium consisting of Blackstone Group, Carlyle Group, KKR & Co and Temasek Holdings.

Deutsche Bank Securities and Moelis & Co advised Life Tech.

Wachl, Lipton, Rosen and Katz and WilmerHale are legal counsel to Thermo Fisher, and Cravath, Swaine and Moore is legal counsel to Life Tech.

(Reporting by Michele Gershberg in New York, Esha Dey in Bangalore and Susan Kelly in Chicago; Editing by Maureen Bavdek and Lisa Von Ahn)

在线客服
返回顶部